Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2016.
View HTML
Toggle Summary Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2016 Financial Results Conference Call With Webcast
SAN DIEGO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2016 financial results after the market closes
View HTML
Toggle Summary Vital Therapies Provides Corporate Update
SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provided a corporate update. As of yesterday, 38 subjects have been enrolled at sites
View HTML
Toggle Summary Vital Therapies Announces Third Quarter Financial Results
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the third quarter ended September 30, 2016.
View HTML
Toggle Summary Vital Therapies Announces Upcoming Third Quarter Financial Results Conference Call With Webcast
SAN DIEGO, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2016 financial results after the market closes on Thursday,
View HTML
Toggle Summary Vital Therapies Provides Corporate Update
SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provided a corporate update. VTL-308 Enrollment Update As of today, 14 subjects have
View HTML
Toggle Summary Vital Therapies Announces Appointment of Former Receptos President and CEO Faheem Hasnain to Its Board of Directors
SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that Faheem Hasnain has been appointed to its Board of Directors, effective
View HTML
Toggle Summary Vital Therapies Announces Second Quarter Financial Results
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2016.
View HTML
Toggle Summary Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2016 financial results after the market closes on Tuesday,
View HTML
Toggle Summary Vital Therapies Enrolls First Subject in VTL-308
SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the first subject was recently enrolled in its phase 3 trial designated
View HTML